Search
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]
Hydroxyproline
go.drugbank.com/drugs/DB08847ApprovedTherapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds. … It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalAlthough multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment
LS11
go.drugbank.com/drugs/DB05918InvestigationalLS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalALK-inhibitor on December 18, 2024. … [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib].
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnAn inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). … It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011.
Cortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigationalCortisone acetate was first isolate in 1935 and became more widely researched in 1949. … [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Hyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was approved for use by the FDA in August, 2007.